Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol

Cardiovascular Research

Volumn 44, Issue 2, 1999, Pages 303-314

  Merot, Jocelyn ^a,b   Charpentier, Flavien ^a   Poirier, Jean Marie ^d   Coutris, G érard ^c   Weissenburger, Jacques ^d  

^a INSERM   (France)

^b LUNAM UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Antiarrhythmic agents; Arrhythmia (mechanisms); ECG; Ventricular arrhythmias

Indexed keywords

AMIODARONE; HALOTHANE; LIOTHYRONINE; SOTALOL; THYROXINE;

ACTION POTENTIAL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; CONTROLLED STUDY; DOG; DOSE RESPONSE; ELECTROCARDIOGRAM; ELECTROPHYSIOLOGY; HEART ATRIUM PACING; HEART VENTRICLE CONDUCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; REPOLARIZATION;

EID: 0033231798     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00232-1     Document Type: Article

References (54)

1. Vaughan-Williams E.M. Classification of anti-dysrhythmic drugs. Pharmacol Ther. 1:1975;115-138.
2. Singh N., Vaughan-Williams E.M. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 39:1970;657-667.
3. Zipes D.P., Prystowsky E.N., Heger J.J. Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. J Am Coll Cardiol. 3:1984;1059-1071.
4. Follmer C.H., Aomine M., Yeh J.Z., Singer D.H. Amiodarone-induced block of sodium current in isolated cardiac cells. J Pharmacol Exp Ther. 243:1987;187-194.
5. Nishimura M., Follmer C.H., Singer D.H. Amiodarone blocks calcium current in single guinea pig ventricular myocytes. J Pharmacol Exp Ther. 251:1989;650-659.
6. Coker S.J., Chess W.R. Amiodarone, adrenoceptor responsiveness and ischemia- and reperfusion-induced arrhythmias. Eur J Pharmacol. 201:1991;103-109.
7. Kennedy K.L., Griffiths H., Gray T.A. Amiodarone and the thyroid. Clin Chem. 35:1989;1882-1887.
8. Polster P., Broekhuisen J. The adrenergic antagonism of amiodarone. Biochem Pharmacol. 25:1976;131-134.
9. Ikeda N., Nademanee K., Kannan R., Singh B.N. Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentrations. Am Heart J. 108:1984;890-898.
10. Morady F., DiCarlo L.A., Krol R.B., Baerman J.M., Buitleir M. Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol. 7:1986;148-157.
11. Wellens H.J.J., Brugada P., Abdollah H., Dassen W.R. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation. 69:1984;120-127.
12. Nademanee K., Hendrickson J.A., Kannan R., Singh B.N. Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening arrhythmias. Am. Heart J. 103:1982;950-959.
13. Gross S.A., Somani P. Amiodarone-induced ultrastructural changes in canine myocardial fibers. Am. Heart J. 112:1986;771-779.
14. Hohnloser S.H., Klingenheben T., Singh B.N. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med. 121:1994;529-535.
15. Hohnloser S.H., Singh B.N. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors and clinical implications. J. Cardiovasc Electrophysiol. 6:1995;920-936.
16. Chézalviel F., Weissenburger J., Guhennec C., et al. Antiarrhythmic effect of a sotalol mexiletine combination on induced ventricular tachycardia in dogs. J Cardiovasc Pharmacol. 21:1993;212-220.
17. Chézalviel-Guilbert F., Davy J-M., Poirier J-M., Weissenburger J. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. J Am Coll Cardiol. 26:1995;787-792.
18. Shimizu W., Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation. 96:1997;2038-2047.
19. Sicouri S., Moro S., Litovsky S., Elizari M.V., Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol. 8:1997;1269-1279.
20. Drouin E., Lande G., Charpentier F. Amiodarone reduces transmural heterogeneity of repolarization in the human heart. J Am Coll Cardiol. 32:1998;1063-1068.
21. Antzelevitch C., Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsades de pointes. J Am Coll Cardiol. 23:1994;259-277.
22. Nesterenko V., Weissenburger J. Experimental evidence for re-interpretation of basis for the monophasic action potential: a new technique with large amplitude and stable transmural signals. Circulation. 92:1995;I-299.
23. Nesterenko V., Antzelevitch C. Spatial resolution of newly developed MAP recording techniques: Experimental evaluation in highly heterogeneous myocardium in vitro. Pac Clin Electrophysiol. 21:1998;II-857.
24. Horner S.M., Vespalcova Z., Lab M.J. Electrode for recording direction of activation, conduction velocity, and monophasic action potential of myocardium. Am J Physiol. 272:1997;H1917-H1927.
25. Weissenburger J., Davy J.-M., Chézalviel F., et al. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokaliemic dogs with atrioventricular block-comparison between quinidine, lidocaine, flecainide, propanolol and sotalol. J Pharmacol Exp Ther. 259:1991;871-883.
26. Weissenburger J, Nesterenko VV, Antzelevitch C. Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo. Torsade de Pointes develops with halothane but not pentobarbital anesthesia. Submitted for publication.
27. Jandreski M.A., Vanderslice W.E. Clinical measurement of serum amiodarone and desethylamiodarone by using solid-phase extraction followed by HPLC with a high-carbon reversed-phase column. Clin Chem. 39:1993;496-500.
28. Drouin E., Charpentier F., Gauthier C., Laurent K., Le Marec H. Electrophysiologic characteristics of cells spanning the left ventricular wall of human heart: evidence for the presence of M cells. J Am Coll Cardiol. 26:1995;158-192.
29. Latini R., Connolly S.J., Kates R.E. Myocardial disposition of amiodarone in the dog. J. Pharmacol Exp Ther. 224:1983;603-608.
30. Figge H.L., Figge J. The effects of amiodarone on thyroid hormone function: a review of the physiology and clinical manifestations. J Clin Pharmacol. 30:1990;588-595.
31. Nattel S., Talajic M., Fermini B., Roy D. Amiodarone: pharmacology, clinical actions, and relationships between them. J Cardiovasc Electrophysiol. 3:1992;266-280.
32. Roden D.M. Pharmacokinetics of amiodarone: implications for drug therapy. Am J Cardiol. 72:1993;45F-50F.
33. Anderson K.P., Walker R., Dustman T., et al. Rate-related electrophysiologic effects of long-term administration of amiodarone on canine ventricular myocardium in vivo. Circulation. 79:1989;948-958.
34. Abdollah H., Brien J.F., Brennan F.J. Antiarrhythmic effect of chronic oral amiodarone treatment in dogs with myocardial infarction and reproducibly inducible sustained ventricular arrhythmias. J Cardiovasc Pharmacol. 15:1990;799-807.
35. Brien J., Jimmo S., Brennam F., Armstrong P., Abdollah H. Disposition of amiodarone and its proximate metabolite, desethylamiodarone, in the dog for oral administration of single dose and short-term drug regimen. Drug Metab Dispos. 18:1990;846-851.
36. Patterson E., Eller B.T., Abrams G.D., Vasiliades J., Lucchesi B.R. Ventricular fibrillation in a conscious canine preparation of sudden coronary death - prevention by short- and long-term amiodarone administration. Circulation. 68:1983;857-864.
37. Adams P.C., Holt D.W., Storey G.C.A., et al. Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation. 72:1985;1064-1075.
38. Plomp T.A., Hauer R.N.W., Robles de Medina E.O. Amiodarone and desethylamiodarone concentrations in plasma and tissues of surgically treated patients on long term oral amiodarone treatment. In Vivo. 4:1990;97-100.
39. Giardina E.G., Schneider M., Barr M.L. Myocardial amiodarone and desethylamiodarone concentrations in patients undergoing cardiac transplantation. J Am Coll Cardiol. 16:1990;943-947.
40. Greenberg M.L., Lerman B.B., Shipe J.R., Kaiser D.L., DiMarco J.P. Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity. J Am Coll Cardiol. 9:1987;1148-1155.
41. Papp J.G., Nemeth M., Krassoi I., Mester L., Hala O., Varro A. Differential electrophysiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle. J Cardiovasc Pharmacol Therapeut. 1:1996;287-296.
42. Sosunov E.A., Anyukhovsky E.P., Rosen M.R. Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium. I. In vitro study. Circulation. 96:1997;4011-4018.
43. Anyukhovsky E.P., Sosunov E.A., Feinmark S.J., Rosen M.R. Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium II In vivo study. Circulation. 96:1997;4011-4018.
44. Shimizu W., Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation. 24:(98):1998;2314-2322.
45. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 92:1995;3381-3386.
46. Chézalviel-Guilbert F., Deplanne V., Davy J.M., et al. Combination of sotalol and quinidine in a canine model of torsades de pointes: no increase in the QT-related proarrhythmic action of sotalol. J Cardiovasc Electrophysiol. 9:1998;498-507.
47. Surawicz B. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations? J Am Coll Cardiol. 14:1989;172-184.
48. Antzelevitch C., Sun Z.-Q., Zhang Z.-Q., Yan G.-X. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsades de pointes. J Am Coll Cardiol. 28:1996;1836-1848.
49. El-Sherif N., Caref E.B., Yin H., Restivo M. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. Circ Res. 79:1996;474-492.
50. Wang Q., Shen J., Splawski I., et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 80:1995;805-811.
51. Marchlinski F., Buxton A., Miller J., et al. Amiodarone versus amiodarone and a type Ia agent for treatment of patients with rapid ventricular tachycardia. Circulation. 74:1986;1037-1043.
52. Rae A.P., Greenspan A.M., Spielman S., et al. Antiarrhythmic drug efficacy for ventricular tachyarrhythmias associated with coronary artery disease as assessed by electrophysiologic studies. Am J Cardiol. 55:1985;1494-1499.
53. Dorian P., Newman D., Berman N. Prolongation of ventricular refractoriness predicts suppression of ventricular tachycardia inducibility. Pac Clin Electrophysiol. 15:1992;552. Abstract.
54. Sicilian Gambit. The search for novel antiarrhythmic strategies. Eur Heart J 1998;19:1178-1196.